DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vaqta (Hepatitis A Vaccine Inactivated) - Published Studies

 
 



Vaqta Related Published Studies

Well-designed clinical trials related to Vaqta (Hepatitis A Vaccine)

Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. [2011.04]

Comparative immunogenicity of two vaccination schedules of a combined hepatitis A and B vaccine in healthy volunteers. [2011.04]

Antibody persistence and immune memory 4 years post-vaccination with combined hepatitis A and B vaccine in adults aged over 40 years. [2011.03]

The use of dried blood spots for assessing antibody response to hepatitis A virus after natural infection and vaccination. [2011.02]

A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. [2010.10]

Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents. [2010.08.23]

Predictors of hepatitis knowledge improvement among methadone maintained clients enrolled in a hepatitis intervention program. [2010.08]

Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years. [2010.06.17]

Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States. [2010.06]

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study. [2009.07.16]

Effects of a nurse-managed program on hepatitis A and B vaccine completion among homeless adults. [2009.01]

Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. [2008.11.01]

[Immunogenicity and safety of three consecutive lots on an inactivated hepatitis A vaccine: a double-blind, immunogenicity and safety of three consecutive lots on a inactivated hepatitis A vaccine:a double-blind, randomized and controlled trial in children] [2008.06]

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. [2008.05]

Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. [2008.05]

Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial. [2008.04.24]

Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. [2008.03.25]

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. [2008.03.04]

Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. [2008.01.30]

Immunogenicity and safety of combined intradermal recombinant Hepatitis B with BCG vaccines at birth. [2008.01.30]

One arm or two? Concurrent administration of meningococcal C conjugate and hepatitis B vaccines in pre-teens. [2008.01]

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. [2007.12.12]

Comparison of accelerated and rapid schedules for monovalent hepatitis B and combined hepatitis A/B vaccines in children with cancer. [2007.12]

Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. [2007.11]

Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. [2007.10.25]

Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine. [2007.10]

Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant. [2007.10]

Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study. [2007.10]

Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. [2007.09]

Hepatitis B vaccination of newborn infants in rural China: evaluation of a village-based, out-of-cold-chain delivery strategy. [2007.09]

Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure. [2007.09]

Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years. [2007.08]

Cellular and humoral immune response to a third generation hepatitis B vaccine. [2007.08]

Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. [2007.08]

Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. [2007.07]

Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India. [2007.06.14]

Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. [2007.05]

Vitamin A Supplementation Enhances Infants' Immune Responses to Hepatitis B Vaccine but Does Not Affect Responses to Haemophilus influenzae Type b Vaccine. [2007.05]

Safety and efficacy of a recombinant hepatitis E vaccine. [2007.03.01]

Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules. [2007.01.02]

Rapid and sustained immune response against hepatitis a and B achieved with combined vaccine using an accelerated administration schedule. [2007.01]

Predisposing, reinforcing and enabling factors associated with hepatitis B testing in Chinese Canadians in British Columbia. [2007.01]

Low dose intradermal vaccination is superior to high dose intramuscular vaccination for hepatitis B in unresponsive hemodialysis patients. [2007]

Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. [2006.06.29]

Interchangeability of Hepatitis A boosters, Avaxim and Vaqta, in healthy adults following a primary dose of the combined typhoid/Hepatitis A vaccine Viatim. [2006.05.15]

Long-term immunity in young adults after a single dose of inactivated Hepatitis A vaccines. [2006.05.15]

Long-term protective effect of post-exposure Havrix administration during viral hepatitis Type A outbreaks. [2006]

Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years. [2005.11]

Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1-11-year-old children. [2005.10.17]

A two-dose schedule for combined hepatitis A and B vaccination in children aged 6-15 years. [2005.04.22]

Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. [2005.03.31]

Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. [2004.11.15]

A randomized, open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults. [2004.07]

Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. [2004.03]

Simultaneous vaccination against hepatitis A and B: results of an open, randomized study from the occupational health point of view. [2004]

A combined dual-chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults. [2003.12.01]

Immunogenicity and safety of two doses of a paediatric hepatitis A vaccine in thai children: comparison of three vaccination schedules. [2003.12]

[The study on the 0, 12 month vaccination schedule' of Healive inactivated hepatitis A vaccine in children] [2003.11]

[Comparison of two different vaccination schemes against Hepatitis A and B in Mexican children and adolescents.] [2003.10]

Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies. [2003.09.08]

Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. [2003.09.01]

Hepatitis A and B vaccination in a sexually transmitted disease clinic for men who have sex with men. [2003.09]

Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. [2003.09]

Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. [2003.04.15]

Immunogenicity and safety of a new inactivated hepatitis A vaccine in young adults: a comparative study. [2002.10]

Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 12-15 years. [2002.06.07]

Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in healthy Chilean subjects. [2002.06]

[Immunogenicity and efficacy of two live attenuated hepatitis A vaccines (H(2) strains and LA-1 strains)] [2002.05.25]

Immunogenicity and reactogenicity of a combined high dose hepatitis A and hepatitis B vaccine, compared to that of Twinrix in healthy Indian children. [2002.05.15]

Combined vaccination against hepatitis A, hepatitis B, and typhoid fever: safety, reactogenicity, and immunogenicity. [2002.05]

An open randomized study of inactivated hepatitis A vaccine administered concomitantly with typhoid fever and yellow fever vaccines. [2002.03]

A new accelerated vaccination schedule for rapid protection against hepatitis A and B. [2002.01.15]

A two-dose combined vaccine against hepatitis A and hepatitis B in healthy children and adolescents compared to the corresponding monovalent vaccines. [2002.01]

[Safety and immunogenicity of a new inactivated hepatitis A vaccine] [2001.12]

[A field evaluation of the epidemiological efficacy of an attenuated live hepatitis A vaccine (H2 strain)] [2001.11]

Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomised study. [2001.09.14]

A randomized study of a flexible booster dosing regimen of VAQTA in adults: safety, tolerability, and immunogenicity. [2001.09.14]

A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. [2001.09.14]

A randomised comparison of two inactivated hepatitis A vaccines, Avaxim and Vaqta, given as a booster to subjects primed with Avaxim. [2001.08.14]

Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix. [2001.02.01]

Randomized controlled trial of concurrent hepatitis A and B vaccination. [2001.02]

Comparison of the reactogenicity and immunogenicity of a two injection combined high-dose hepatitis A and hepatitis B vaccine to those of Twinrix. [2000.12.08]

Different HBs antibody versus lymphoproliferative responses after application of a monovalent (hepatitis B) or combined (hepatitis A + hepatitis B) vaccine. [2000.12]

Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. [2000.11.22]

Immunogenicity and reactogenicity of the combined hepatitis A and B vaccine in young adults. [2000.10.15]

A single dose, combined vaccine against typhoid fever and hepatitis A: consistency, immunogenicity and reactogenicity. [2000.09]

Dose range evaluation of a new inactivated hepatitis A vaccine administered as a single dose followed by a booster. [2000.08.15]

[Primary study on immunologic effect of live attenuated hepatitis A vaccine (H2 strain) after booster dose] [2000.04]

Hepatitis A vaccine administration: comparison between jet-injector and needle injection. [2000.03.17]

Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia. [2000.03]

Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines. [2000.01.06]

[Further survey on efficacy of attenuated live hepatitis A vaccines] [2000.01]

Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years. [1999.12]

Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. [1999.12]

A two dose combined hepatitis A and B vaccine in Chinese youngsters. [1999.09]

Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults. [1999.05.04]

Comparative immunogenicity and tolerance of Vaqta and Havrix. [1999.04.23]

Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial. [1999.04.03]

Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults. [1999.03.17]

Hepatitis A vaccine in healthy adults: a comparison of immunogenicity and reactogenicity between two- and three-dose regimens. [1999.01]

Comparison of two immunization schedules with an inactivated hepatitis A vaccine (AvaximTM). [1998.12]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017